Form 4: Pliant Therapeutics General Counsel Sells Shares Under 10b5-1 Plan

Pliant Therapeutics' General Counsel, Mike Ouimette, sold a total of 23,500 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Summary

• Mike Ouimette, General Counsel and Corporate Secretary of Pliant Therapeutics, Inc., sold 13,270 shares of common stock on January 17, 2025, at a weighted average price of $11.2011 per share.
• These shares were sold to cover withholding tax liabilities related to the vesting of restricted stock units.
• A further 10,230 shares were sold on January 22, 2025, at a weighted average price of $10.9934 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on August 26, 2024.
• The total shares sold by Mr. Ouimette was 23,500.

Sentiment

Score: 5

Explanation: The document reflects a routine insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's overall prospects.

Industry Context

This is a routine filing for insider stock sales, often seen in publicly traded companies. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, such as those in the biotechnology sector like Pliant Therapeutics.
• Similar filings are regularly made by executives at companies like Gilead Sciences, Amgen, and Biogen, when they sell shares under pre-arranged plans.
• The reported price ranges are typical for market fluctuations during trading days.

Stakeholder Impact

• The stock sales may have a minor impact on the share price, but the use of a 10b5-1 plan suggests no material impact on the company's operations or future prospects.

Key Dates

Keywords

Pliant Therapeutics, insider trading, Form 4, Rule 10b5-1, stock sale, equity securities, Mike Ouimette, General Counsel